DCPH Stock Overview
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Deciphera Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.71 |
| 52 Week High | US$22.76 |
| 52 Week Low | US$6.51 |
| Beta | 0.69 |
| 1 Month Change | -22.67% |
| 3 Month Change | 10.30% |
| 1 Year Change | 104.78% |
| 3 Year Change | -75.73% |
| 5 Year Change | -42.22% |
| Change since IPO | -5.33% |
Recent News & Updates
Recent updates
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29
Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%
Feb 11
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Feb 05Deciphera to expand geographic reach and clinical potential of ripretinib
Jan 11Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 15Deciphera completes enrollment in late-stage study of ripretinib in GIST patients
Nov 30Shareholder Returns
| DCPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | -0.8% | 0.9% |
| 1Y | 104.8% | 3.9% | -10.9% |
Return vs Industry: DCPH exceeded the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: DCPH exceeded the US Market which returned -9.6% over the past year.
Price Volatility
| DCPH volatility | |
|---|---|
| DCPH Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DCPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: DCPH's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 280 | Steve Hoerter | https://www.deciphera.com |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Deciphera Pharmaceuticals, Inc. Fundamentals Summary
| DCPH fundamental statistics | |
|---|---|
| Market Cap | US$1.26b |
| Earnings (TTM) | -US$221.39m |
| Revenue (TTM) | US$121.89m |
10.3x
P/S Ratio-5.7x
P/E RatioIs DCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCPH income statement (TTM) | |
|---|---|
| Revenue | US$121.89m |
| Cost of Revenue | US$198.53m |
| Gross Profit | -US$76.64m |
| Other Expenses | US$144.75m |
| Earnings | -US$221.39m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 07, 2023
| Earnings per share (EPS) | -2.94 |
| Gross Margin | -62.88% |
| Net Profit Margin | -181.63% |
| Debt/Equity Ratio | 0% |
How did DCPH perform over the long term?
See historical performance and comparison